Cheryl Gault - Rapport Therapeutics, Chief Officer
| RAPP Stock | 24.00 1.16 5.08% |
Executive
Cheryl Gault is Chief Officer of Rapport Therapeutics, Common
| Age | 45 |
| Address | 1325 Boylston Street, Boston, MA, United States, 02215 |
| Phone | 857 321 8020 |
| Web | https://www.rapportrx.com |
Cheryl Gault Latest Insider Activity
Tracking and analyzing the buying and selling activities of Cheryl Gault against Rapport Therapeutics, stock is an integral part of due diligence when investing in Rapport Therapeutics,. Cheryl Gault insider activity provides valuable insight into whether Rapport Therapeutics, is net buyers or sellers over its current business cycle. Note, Rapport Therapeutics, insiders must abide by specific rules, including filing SEC forms every time they buy or sell Rapport Therapeutics,'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Cheryl Gault 2 days ago Disposition of tradable shares by Cheryl Gault of Cyclerion Therapeutics subject to Rule 16b-3 | ||
Cheryl Gault few days ago Disposition of 568 shares by Cheryl Gault of Cyclerion Therapeutics at 19.04 subject to Rule 16b-3 | ||
Cheryl Gault over three weeks ago Disposition of 1999 shares by Cheryl Gault of Cyclerion Therapeutics at 14.87 subject to Rule 16b-3 | ||
Cheryl Gault over two months ago Disposition of 257 shares by Cheryl Gault of Cyclerion Therapeutics at 11.95 subject to Rule 16b-3 |
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Suzy Arrabito | Reservoir Media | N/A | |
| Ricardo Yanez | Grupo Televisa SAB | 51 | |
| Guy Aharonov | Ituran Location and | 58 | |
| Justin Schmid | Digi International | N/A | |
| Brian Ballenger | Digi International | N/A | |
| Brian Kirkendall | Digi International | N/A | |
| Udi Mizrahi | Ituran Location and | 52 | |
| Steve Ericson | Digi International | N/A | |
| Joel Vengco | Digi International | N/A | |
| Juan Newman | Grupo Televisa SAB | N/A | |
| Guy Yehiav | Digi International | N/A | |
| James Heindlmeyer | Reservoir Media | 51 | |
| Juan Aguilar | Grupo Televisa SAB | N/A | |
| Rodrigo Villanueva | Grupo Televisa SAB | N/A | |
| Gary Marks | Digi International | 66 | |
| Shahar Sheratzky | Ituran Location and | 43 | |
| Giovanni Rier | Grupo Televisa SAB | N/A | |
| Terrence Schneider | Digi International | 58 | |
| Carlos Margain | Grupo Televisa SAB | 50 | |
Rapport Therapeutics, Leadership Team
Elected by the shareholders, the Rapport Therapeutics,'s board of directors comprises two types of representatives: Rapport Therapeutics, inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Rapport. The board's role is to monitor Rapport Therapeutics,'s management team and ensure that shareholders' interests are well served. Rapport Therapeutics,'s inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Rapport Therapeutics,'s outside directors are responsible for providing unbiased perspectives on the board's policies.
| Troy Ignelzi, Chief Officer | ||
| Bradley MD, Chief Officer | ||
| Cheryl Gault, Chief Officer | ||
| Swamy Yeleswaram, Chief Officer | ||
| Steven MD, Founder Chairman | ||
| Abraham MBA, President CEO | ||
| Kathleen Wilkinson, Chief Officer | ||
| Karina Chmielewski, Chief Operations | ||
| Julie DiCarlo, Head Relations | ||
| David MD, Founder Officer |
Rapport Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Rapport Therapeutics, a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Current Valuation | 427.93 M | ||||
| Shares Outstanding | 36.58 M | ||||
| Shares Owned By Insiders | 6.53 % | ||||
| Shares Owned By Institutions | 93.47 % | ||||
| Number Of Shares Shorted | 1.74 M | ||||
| Price To Book | 2.26 X | ||||
| EBITDA | (34.66 M) | ||||
| Net Income | (34.79 M) | ||||
| Total Debt | 2.15 M | ||||
| Book Value Per Share | 9.21 X |
Pair Trading with Rapport Therapeutics,
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Rapport Therapeutics, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Rapport Therapeutics, will appreciate offsetting losses from the drop in the long position's value.Moving against Rapport Stock
| 0.48 | FATE | Fate Therapeutics | PairCorr |
| 0.38 | FENC | Fennec Pharmaceuticals | PairCorr |
| 0.37 | VRCA | Verrica Pharmaceuticals | PairCorr |
| 0.35 | A | Agilent Technologies | PairCorr |
| 0.34 | VRAX | Virax Biolabs Group | PairCorr |
The ability to find closely correlated positions to Rapport Therapeutics, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Rapport Therapeutics, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Rapport Therapeutics, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Rapport Therapeutics, Common to buy it.
The correlation of Rapport Therapeutics, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Rapport Therapeutics, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Rapport Therapeutics, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Rapport Therapeutics, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Rapport Stock Analysis
When running Rapport Therapeutics,'s price analysis, check to measure Rapport Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rapport Therapeutics, is operating at the current time. Most of Rapport Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Rapport Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rapport Therapeutics,'s price. Additionally, you may evaluate how the addition of Rapport Therapeutics, to your portfolios can decrease your overall portfolio volatility.